3 September 2025 in Dermatology and Therapy
Introduction Androgenetic alopecia (AGA) is a chronic, progressive condition often resistant to conventional treatments. Transdermal delivery systems such as iontophoresis and skin patting (SPi) may enhance drug penetration and follicular targeting. Dutasteride, a potent dual 5α-reductase inhibitor, has shown superior efficacy to finasteride, but topical delivery is limited by variable absorption. In this pilot study, we evaluated the efficacy and safety of dutasteride gel delivered via SPi and iontophoresis in men and postmenopausal women with treatment-resistant AGA. Methods In this single-center pilot study, 20 adults (10 males, 10 postmenopausal females) with AGA unresponsive to ≥ 12 months of standard therapy underwent four monthly sessions of SPi and iontophoresis with 6% dutasteride gel. Hair density, shaft diameter, and pull test results were assessed at baseline and 8 weeks post-treatment; patient satisfaction (0–4 scale) and safety were recorded. Paired tests were used to analyze the results, with p < 0.05 considered to indicate significance. Results Hair density improved significantly in frontal (p < 0.001) and vertex (p < 0.001) regions. Shaft diameter increased in vertex (p < 0.001) and frontal areas (p = 0.046). Pull test scores improved (p < 0.001). Mean satisfaction was 3.4/4. No adverse events occurred. Conclusion SPi with iontophoresis effectively delivered topical dutasteride, yielding significant clinical improvement and excellent safety in treatment-resistant AGA. Larger randomized trials are warranted to confirm these findings.
7 October 2026 in Dermatology and Therapy
Introduction Hand–foot syndrome (HFS) is a frequent and potentially dose-limiting adverse event of capecitabine. Current therapeutic strategies are not always effective. Since inflammatory pathways, including JAK-STAT3 signaling, may contribute to capecitabine-induced HFS, topical JAK inhibition could represent a potential therapeutic approach. Methods We report two women with metastatic breast cancer receiving capecitabine monotherapy who developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 HFS involving both palms and soles. Both patients had previously received clobetasol propionate 0.05% combined with urea 30%, with only transient benefit. Delgocitinib 20 mg/g cream was subsequently applied twice daily to palms and soles for 6 weeks. Treatment response was assessed clinically and using the HFS-14 quality-of-life scale. Results Capecitabine dose and schedule remained unchanged in both patients throughout the 6-week delgocitinib treatment period. In patient 1, HFS improved from CTCAE grade 3 to grade 1, with marked symptomatic improvement and a decrease in HFS-14 score from 73.5 to 17.6. Capecitabine was continued unchanged, and the clinical improvement remained stable during an additional 3 months of follow-up. In patient 2, erythema decreased, but desquamation and burning persisted; HFS remained CTCAE grade 3 and the HFS-14 score decreased from 76.5 to 67.6. Capecitabine was therefore interrupted after the week 6 assessment. No local or systemic adverse events related to delgocitinib were observed. Conclusion Topical delgocitinib may represent a potential therapeutic strategy for capecitabine-induced HFS, particularly in patients who do not adequately respond to topical corticosteroid therapy. However, the discordant responses observed in these two cases highlight that its therapeutic role remains uncertain and requires further prospective investigation.
17 June 2026 in Journal of the European Academy of Dermatology and Venereology
31 August 2026 in Journal of the European Academy of Dermatology and Venereology